Biomarkers Predictive of Therapeutic Benefit 3

• 2431 · PDF Clinical outcome of patients with early stage and metastatic non-small cell lung cancer (NSCLCa) harboring high genomic scarring score (GSS) Panteleimon Konstantoulakis, Georgia Christopoulou, Apostolos Klinakis, Katerina Tsilingiri, Ioannis Vatselas, Natalia Asimakopoulou, Vassilis Georgoulias, Ioannis Pateras, Konstantinos Ntostoglou, Georgios Christodoulopoulos, Athanasios Kotsakis, Vasiliki Anastasopoulou, Dora Hatzidaki, Abdriani Harpidou, Emilia Tsaroucha, Gary Karponi
• 2432 · PDF Precision genomics in leukemiareveals mutational and fusion landscapes in South Asian patients driving clinical decisions Puja Sinha, Amit Kumar, Shobit Gupta, Rama Chandran, Giulliana Tessarin
• 2433 · PDF BAP1 loss confers ferroptosis resistance to cholangiocarcinoma via TLCD1-mediated membrane phospholipid remodeling Yu Zhao, Peyton Classon, Danielle Marie Carlson, Jayla Millender, Irene K. Yan, Sumera Ilyas, Rory L. Smoot, Gregory J. Gores, TUSHAR PATEL, Davide Povero
• 2434 · PDF Prognostic and predictive effects of TP53 co-mutations and RET fusion partners in RET -rearranged advanced NSCLC Daniela Miliziano, Julia K. Rotow, Meghanne Lomibao, Tolulope Adeyelu, Arianna Marinello, Helena Bote-de Cabo, Jamie Feng, Andrea De Giglio, Mariana Brandão, Florian Guisier, Michael Duruisseaux, Christina Falcon, Massimiliano Cani, Francesca Colamartini, Barliz Waissengrin, Isabelle Monnet, Anna Eisert, Emilio Bria, Amin H. Nassar, Ayesha Aijaz, Patricia Iranzo, Colin R. Lindsay, Elizabeth Fabre, Vladmir Cordeiro de Lima, Judith Raimbourg, Laura Mezquita, Nicolas Minatta, Sophie Cousin, Katarzyna Szymczak, Vincent Fallet, Clarisse Audigier-Valette, Helene Doubre, Philippe Rochigneux, Annarita Avanzo, Antonio Calles, Marco Tagliamento, Diego Cortinovis, Balazs Halmos, Nicholas Girard, Andrew Elliott, Jair Bar, Alessio Cortellini, Diana N. Ionescu, Frances A. Shepherd, Fabrice Barlesi, Karen L. Reckamp, David Planchard, Benjamin Besse, Alexander Drilon, Mihaela Aldea
• 2435 · PDF Tertiary lymphoid structures induction predicts and enhances response to famitinib plus PD-L1 blockade in advanced thyroid cancer Wei Kou, Yue Che, Qiwu Zhao, Haoran Feng, Zhuoran Liu, Jie Kuang, Weihua Qiu
• 2436 · PDF Gastric cancer-derived tertiary lymphoid structure score from single-cell spatial transcriptomics with pan-cancer validation for immunotherapy response Wenbo Zhu, Hongru Shen, Huijun Wang, Ben Liu, Xiangchun Li, Kexin Chen
• 2437 · PDF A comparative scoring framework for BCMA-, GPRC5D- and CD38-targeted therapies in multiple myeloma Konstantin Chernyshov, Stanislav Kurpe, Maria Kuzmicheva, Kseniia Fede, Sargis Margaryan, Daria Goncharova, Anastasiya Evdokimova, Dmitry Grachev, Oleg Baranov, Polina Turova, Alexander Nesmelov, Andrey Kravets, Eduardo Shugaev-Mendosa, Nikita Kotlov
• 2438 · PDF Discovery of predictive circulating proteomic biomarkers for therapy response in HRR-driven solid tumors Anamarija Pfeiffer, Wouter van Bergen, Martin Mehnert, Polina Shichkova, Vanessa Bühlmann, Amaury Lachaud, Yuehan Feng, Takayuki Yoshino, Norio Nonomura, Taigo Kato
• 2439 · PDF Predictive modeling of venetoclax/azacitidine response in acute myeloid leukemia using inflammatory cytokine profiling and clinical data from the NCT04267081 trial cohort Ankita Srivastava, Bahar Tercan, David L. Gibbs, Heikki Kuusanmäki, Mika Kontro, Caroline A. Heckman, Guangrong Qin
• 2440 · PDF Single-cell MRD profiling identifies CXCR4-high AML as a responder population to CXCR4 inhibition with Motixafortide Enise Ceran, Sonia Jaramillo-Segura, Anne Kahtrin Merbach, Christian Rohde, Robert Durruthy-Durruthy, Adam Sciambi, Marc Arribas-Layton, Michelle Lotze, Maxi Wass, Kathrin Rieger, Mathias Hänel, Regina Herbst, Christoph Röllig, Edgar Jost, Richard Schlenk, Katharina Götze, Marina Scheller, Marion Subklewe, Simone Kowoll, Jörg Steighardt, Bayram Edemir, Lutz P. Müller, Irit Glicko-Kabir, Abi Vainstein-Haras, Cora Gromann, Ella Sorani, Shaul Kadosh, Andreas Wienke, Claudia Baldus, Uwe Platzbecker, Hubert Serve, Martin Bornhäuser, Carsten Müller-Tidow
• 2441 · PDF The myCAF and ECM landscape in KRAS-mutated cancer: Utilizing liquid biomarkers to track KRAS-induced fibrosis and KRAS inhibitor efficacy Martin Birkmose Rasmussen, Rasmus Sund Pedersen, Nicholas Willumsen, Morten Karsdal
• 2442 · PDF Baseline single-cell mass distributions correlate with clinical response to acalabrutinib, venetoclax, and obinutuzumab in mantle cell lymphoma Mingzeng Zhang, Ye Zhang, Lydie Debaize, Grace Chen, Sona Baghiyan, Shogo Miura, Nezha Senhaji, Juniper Mai, Clare Phinney, Alexa Batingana, Jenalyn Weekes, Salah Abdulkarim, Haocheng Wang, Svitlana Tyekucheva, Jerome Ritz, Christine E. Ryan, Austin I. Kim, Scott R. Manalis, Mark A. Murakami
• 2443 · PDF Urinary pesticide biomarkers and liver disease risk in Thailand: A machine-learning-based risk-prediction model Daxeshkumar P. Patel, Christopher Loffredo, Majda Haznadar, Mohammed Khan, Amelia Parker, Benjarath Pupacdi, Siritida Rabibhadana, Panida Navasumrit, Nirush Lertprasertsuke, Anon Chotirosniramit, Chawalit Pairojkul, Vor Luvira, Ake Pugkhem, Wattana Sukeepaisarnjaroen, Teerapat Ungtrakul, Thaniya Sricharunrat, Kannika Phornphutkul, Frank J. Gonzalez, Anuradha Budhu, Chulabhorn Mahidol, Xin Wei Wang, Mathuros Ruchirawat, Curtis C. Harris, TIGER-LC Consortium
• 2444 · PDF Multi-agent-augmented analysis of PD-1 checkpoint inhibitor response Ada Shaw, Christina Vivelo, Nicholas Dana, Chetan Sood, Michelle Garred, Aqib Hasnain, Shara Balakrishnan, Vivek Adarsh, Hinco Gierman, Erika von Euw
• 2445 · PDF LAPNET-01: Translational results of a Phase 1b evaluating NP137, an inhibitor of the epithelial-to-mesenchymal transition in combination with mFOLFIRINOX for the first-line treatment of locally advanced pancreatic ductal adenocarcinoma Gaël Roth, Pascal Artru, Olivier Bouche, Marc Manceau, Nicolas Williet, Julien Ghelfi, Anthony Turpin, Astrid Lièvre, Jean Frederic Blanc, Camille Evrard, Jean Baptiste Bachet, Pauline Parent, Matthieu Roustit, Hector Hernandez-Vargas, Elise Georges, Sébastien Hazard, Benjamin Ducarouge, Agnès Bernet, Patrick Mehlen
• 2446 · PDF High PRMT5 expression is associated with decreased immune infiltrate and worse outcomes to immune checkpoint inhibitors in non-small cell lung cancer Natalie Vokes, Stamatina Fragkogianni, Pooja A. Shah, Santiago G. Trevino, Konstantinos Leventakos, Lei Deng, Matthew Lee, Tali Azenkot, KAYLA LAYNG, JACOB MERCER, Jyoti Patel, Jordi Rodon Ahnert
• 2447 · PDF Epigenomic liquid biopsy-based biomarkers of platinum and PARP inhibitor response in patients with germ line BRCA-associated PDAC: A pilot study Maria Raitses-Gurevich, Gulfem Guler, Yuhong Ning, Ceyda Coruh, Micah Collins, Shimul Chowdhury, Samuel Levy, Talia Golan
• 2448 · PDF Somatic DDR mutations as potential predictive biomarkers of platinum benefit in metastatic pancreatic cancer Ethan L. Low, Aakash Shah, Eunji Jo, Aliya Lackan, Susan Hilsenbeck, Benjamin L. Musher
• 2449 · PDF Comparison of liquid versus solid tissue genomic profiling for the prediction of chemo-immunotherapy benefit in advanced NSCLC Charu Aggarwal, Prashant Nair, Anagha Jenu, Poornachandra G, Ansu Kumar, Swati Khandelwal, Jyoti Chauhan, Susheel George, Neelsh Lunkad, Vijayashree PS, Nagendra Prasad, Shweta Kapoor, Drew Watson, James Wingrove, Tejas Patil
• 2450 · PDF Peritumoral adipose tissue as a prognostic imaging biomarker for immunotherapy response in HNSCC Kyle Harris, Nazila Godfrey, Dalia El-Gamal, Shesh Rai, Jianmin Pan, Brady Williamson, Trisha Wise-Draper
• 2451 · PDF Dual-function platform for chemotherapy prediction and mutation detection in pancreatic cancer by t CAM-seq Arturo Orlacchio, Erik Ladewig, Adrienne K. Chandra, Anwesha Dhara, Sharon M. James, Steven D. Leach, Kenneth H. Yu, Surajit Dhara
• 2452 · PDF Proteomic aging biomarkers predict survival in immunotherapy-treated tumors Michal Harel, Coren Lahav, Yehonatan Elon, M. Austin Argentieri, Surbhi Singhal, Adam P. Dicker
• 2453 · PDF Valproic acid enhances immune reprogramming in locally advanced rectal cancer: Insights from the VshoRTR3 trial Maria Serena Roca, Elena Di Gennaro, Federica Iannelli, Alfonso De Stefano, Carmen Romano, Francesca Collina, Cristina Testa, Rossella De Cecio, Palmina Bagnara, Susan Costantini, Roberto De Gregorio, Sean Houghton, Shauna Lee Houlihan, Dario Righelli, Andrea Sboner, Alicia Alonso, Antonio Avallone, Alfredo Budillon
• 2454 · PDF A Drug Response Predictor (DRP®) is associated with enhanced overall survival in the phase 2 trial in advanced, recurrent ovarian cancer patients treated twice daily with 2X-121/ Stenoparib (NCT03878849) Steen Knudsen, Annette Nielsen, Thomas Jensen, Peter Gimsing, Anker Hansen, Mogens Winkel Madsen, Michele Gargano, Jose Iglesias, Fernanda Musa, Kathleen N. Moore, Jeremy Graff
• 2456 · PDF Profiling the expression of antibody-drug conjugates in fibrolamellar hepatocellular carcinoma Waqar Arif, Elsa Hallab, Franshisca Hayek, Howard Liu Li, Mari Nakazawa, Mark E. Furth, Andrew S. Liss, Patricia Cogswell, Ezra G. Baraban, Jacqueline Birkness-Gartman, Marina Baretti, Robert A. Anders, Mark Yarchoan

在完整检索应用中浏览本分会场 →